BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35716669)

  • 1. Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas.
    Harpaz N; Mittelman T; Beresh O; Griess O; Furth N; Salame TM; Oren R; Fellus-Alyagor L; Harmelin A; Alexandrescu S; Marques JG; Filbin MG; Ron G; Shema E
    Mol Cell; 2022 Jul; 82(14):2696-2713.e9. PubMed ID: 35716669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.
    Lewis NA; Klein RH; Kelly C; Yee J; Knoepfler PS
    Epigenetics Chromatin; 2022 May; 15(1):18. PubMed ID: 35590427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape.
    Furth N; Algranati D; Dassa B; Beresh O; Fedyuk V; Morris N; Kasper LH; Jones D; Monje M; Baker SJ; Shema E
    Cell Rep; 2022 May; 39(7):110836. PubMed ID: 35584667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Mendez FM; Núñez FJ; Garcia-Fabiani MB; Haase S; Carney S; Gauss JC; Becher OJ; Lowenstein PR; Castro MG
    Neuro Oncol; 2020 Feb; 22(2):195-206. PubMed ID: 32078691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
    Larson JD; Kasper LH; Paugh BS; Jin H; Wu G; Kwon CH; Fan Y; Shaw TI; Silveira AB; Qu C; Xu R; Zhu X; Zhang J; Russell HR; Peters JL; Finkelstein D; Xu B; Lin T; Tinkle CL; Patay Z; Onar-Thomas A; Pounds SB; McKinnon PJ; Ellison DW; Zhang J; Baker SJ
    Cancer Cell; 2019 Jan; 35(1):140-155.e7. PubMed ID: 30595505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
    Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
    Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone H3.3K27M Represses
    Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
    Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
    Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
    Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
    Lu VM; Daniels DJ
    Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation.
    Tatavosian R; Duc HN; Huynh TN; Fang D; Schmitt B; Shi X; Deng Y; Phiel C; Yao T; Zhang Z; Wang H; Ren X
    Nat Commun; 2018 May; 9(1):2080. PubMed ID: 29802243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone H3K27M Mutation in Brain Tumors.
    El-Hashash AHK
    Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
    Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
    Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model.
    Haag D; Mack N; Benites Goncalves da Silva P; Statz B; Clark J; Tanabe K; Sharma T; Jäger N; Jones DTW; Kawauchi D; Wernig M; Pfister SM
    Cancer Cell; 2021 Mar; 39(3):407-422.e13. PubMed ID: 33545065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl alpha-ketoglutarate inhibits proliferation in diffuse intrinsic pontine glioma by reprogramming epigenetic and transcriptional networks.
    Lee K; Yun S; Park J; Lee S; Carcaboso AM; Yi SJ; Kim K
    Biochem Biophys Res Commun; 2023 Oct; 677():6-12. PubMed ID: 37523894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.